371 related articles for article (PubMed ID: 19558486)
1. Intramuscular olanzapine vs. intramuscular short-acting antipsychotics: safety, tolerability and the switch to oral antipsychotic medication in patients with schizophrenia or acute mania.
Chandrasena R; Dvoráková D; Lee SI; Loza N; Mosolov SN; Osváth P; Pregelj P; Walton RJ; Karagianis J; Treuer T
Int J Clin Pract; 2009 Aug; 63(8):1249-58. PubMed ID: 19558486
[TBL] [Abstract][Full Text] [Related]
2. Intramuscular olanzapine versus short-acting typical intramuscular antipsychotics: comparison of real-life effectiveness in the treatment of agitation.
Castle DJ; Udristoiu T; Kim CY; Sarosi A; Pidrman V; Omar AN; Rosales JI; Melamed Y; Isik T; Karagianis J; Treuer T
World J Biol Psychiatry; 2009; 10(1):43-53. PubMed ID: 19137460
[TBL] [Abstract][Full Text] [Related]
3. A prospective, observational study of the safety and effectiveness of intramuscular psychotropic treatment in acutely agitated patients with schizophrenia and bipolar mania.
Perrin E; Anand E; Dyachkova Y; Wagner T; Frediani S; Ballerini A;
Eur Psychiatry; 2012 May; 27(4):234-9. PubMed ID: 20620029
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy.
Wright P; Meehan K; Birkett M; Lindborg SR; Taylor CC; Morris P; Breier A
Clin Ther; 2003 May; 25(5):1420-8. PubMed ID: 12867218
[TBL] [Abstract][Full Text] [Related]
5. Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial.
Huang CL; Hwang TJ; Chen YH; Huang GH; Hsieh MH; Chen HH; Hwu HG
J Formos Med Assoc; 2015 May; 114(5):438-45. PubMed ID: 25791540
[TBL] [Abstract][Full Text] [Related]
6. Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation.
Marder SR; Sorsaburu S; Dunayevich E; Karagianis JL; Dawe IC; Falk DM; Dellva MA; Carlson JL; Cavazzoni PA; Baker RW
J Clin Psychiatry; 2010 Apr; 71(4):433-41. PubMed ID: 20156413
[TBL] [Abstract][Full Text] [Related]
7. Intramuscular olanzapine in patients with schizophrenia: an observational study in an emergency room.
Damsa C; Adam E; Lazignac C; De Gregorio F; Mihai A; Lejeune J; Sarasin F; Allen MH
Bull Soc Sci Med Grand Duche Luxemb; 2008; (2):209-16. PubMed ID: 18561597
[TBL] [Abstract][Full Text] [Related]
8. An observational study of the effectiveness and safety of intramuscular olanzapine in the treatment of acute agitation in patients with bipolar mania or schizophrenia/schizoaffective disorder.
Centorrino F; Meyers AL; Ahl J; Cincotta SL; Zun L; Gulliver AH; Kinon BJ; Houston JP
Hum Psychopharmacol; 2007 Oct; 22(7):455-62. PubMed ID: 17708578
[TBL] [Abstract][Full Text] [Related]
9. Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: A pragmatic double-blind randomized trial.
Kittipeerachon M; Chaichan W
Schizophr Res; 2016 Oct; 176(2-3):231-238. PubMed ID: 27461399
[TBL] [Abstract][Full Text] [Related]
10. Olanzapine monotherapy and olanzapine combination therapy in the treatment of mania: 12-week results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) observational study.
Vieta E; Panicali F; Goetz I; Reed C; Comes M; Tohen M;
J Affect Disord; 2008 Feb; 106(1-2):63-72. PubMed ID: 17582508
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation.
Katagiri H; Fujikoshi S; Suzuki T; Fujita K; Sugiyama N; Takahashi M; Gomez JC
BMC Psychiatry; 2013 Jan; 13():20. PubMed ID: 23311957
[TBL] [Abstract][Full Text] [Related]
12. Single- and multiple-dose pharmacokinetic, safety, and tolerability profiles of olanzapine long-acting injection: an open-label, multicenter, nonrandomized study in patients with schizophrenia.
Mitchell M; Kothare P; Bergstrom R; Zhao F; Jen KY; Walker D; Johnson J; McDonnell D
Clin Ther; 2013 Dec; 35(12):1890-908. PubMed ID: 24184052
[TBL] [Abstract][Full Text] [Related]
13. A post hoc analysis of transitioning to oral treatment with olanzapine or haloperidol after 24-hour intramuscular treatment in acutely agitated adult patients with schizophrenia.
Battaglia J; Houston JP; Ahl J; Meyers AL; Kaiser CJ
Clin Ther; 2005 Oct; 27(10):1612-8. PubMed ID: 16330297
[TBL] [Abstract][Full Text] [Related]
14. A naturalistic comparison study of the efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular levomepromazine in acute agitated patients with schizophrenia.
Suzuki H; Gen K; Takahashi Y
Hum Psychopharmacol; 2014 Jan; 29(1):83-8. PubMed ID: 24424709
[TBL] [Abstract][Full Text] [Related]
15. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia.
Breier A; Meehan K; Birkett M; David S; Ferchland I; Sutton V; Taylor CC; Palmer R; Dossenbach M; Kiesler G; Brook S; Wright P
Arch Gen Psychiatry; 2002 May; 59(5):441-8. PubMed ID: 11982448
[TBL] [Abstract][Full Text] [Related]
16. A double-blind, randomized comparison study of efficacy and safety of intramuscular olanzapine and intramuscular haloperidol in patients with schizophrenia and acute agitated behavior.
Chan HY; Ree SC; Su LW; Chen JJ; Chou SY; Chen CK; Chen YS
J Clin Psychopharmacol; 2014 Jun; 34(3):355-8. PubMed ID: 24743717
[TBL] [Abstract][Full Text] [Related]
17. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia.
Kane JM; Detke HC; Naber D; Sethuraman G; Lin DY; Bergstrom RF; McDonnell D
Am J Psychiatry; 2010 Feb; 167(2):181-9. PubMed ID: 20008947
[TBL] [Abstract][Full Text] [Related]
18. A naturalistic multicenter study of intramuscular olanzapine in the treatment of acutely agitated manic or schizophrenic patients.
San L; Arranz B; Querejeta I; Barrio S; De la Gándara J; Pérez V
Eur Psychiatry; 2006 Dec; 21(8):539-43. PubMed ID: 16697151
[TBL] [Abstract][Full Text] [Related]
19. Baseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective observational safety study.
Jones ME; Andrews JS; Faries DE; Landry J; Xu J; Detke HC; Chhabra-Khanna R; McDonnell DP
BMC Psychiatry; 2015 Nov; 15():278. PubMed ID: 26567159
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole.
Potkin SG; Raoufinia A; Mallikaarjun S; Bricmont P; Peters-Strickland T; Kasper W; Baker RA; Eramo A; Sanchez R; McQuade R
Curr Med Res Opin; 2013 Oct; 29(10):1241-51. PubMed ID: 23822566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
